ASCO VTE Guidelines (& more!)
from OncoPharm Hosted by John Bossaer
Updates on ASCO's updated VTE guidelines with a focus on prophylaxis for ambulatory cancer patients (1:15) and VTE treatment (12:50). Pembrolizumab's latest FDA-approval is discussed (16:00), as is pexidartinib's FDA-approval (18:00), and finally a comparison of BCOP pass rates by training status (22:34).
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of OncoPharm?
This episode is 26 minutes long.
When was this OncoPharm episode published?
This episode was published on August 8, 2019.
Can I download this OncoPharm episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.